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Long-term responders to trastuzumab
monotherapy in first-line HER-2+ advanced
breast cancer: characteristics and survival
data
Sabine Schmid1*, Dirk Klingbiel2, Stefan Aebi3, Aron Goldhirsch4, Christoph Mamot5, Elisabetta Munzone6,
Franco Nolè4, Christian Oehlschlegel7, Olivia Pagani8, Bernhard Pestalozzi9, Christoph Rochlitz10, Beat Thürlimann1,
Roger von Moos11, Patrik Weder1, Khalil Zaman12 and Thomas Ruhstaller1,13
Abstract
Background: The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease
progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory
analysis of the SAKK 22/99 trial was to characterize the specific subset of patients deriving long-term benefit from
trastuzumab monotherapy alone and to identify potential predictive factors of long-term response.
Methods: This is an unplanned post-hoc analysis of patients randomized to Arm A (trastuzumab monotherapy).
Patients were divided in two groups: patients with durable clinical benefit from trastuzumab monotherapy and
short-term responders without durable clinical benefit from trastuzumab monotherapy Univariate and multivariate
analyses of clinical characteristics correlating with response duration was performed.
Results: Eighty six patients were randomized in arm A, 24 patients (28%) were long-term responders and 62 (72%)
were short-term responders with a 5y-overall survival (OS) of 54% (95% CI 31–72) and of 18% (95%CI 10–30),
respectively. Absence of ER expression, absence of PgR expression and presence of visceral disease emerged as
possible negative predictive factors for durable clinical benefit.
Conclusion: Durable clinical benefit can be achieved with trastuzumab monotherapy in a subgroup of HER2-positive
patients with advanced disease and it is predictive for longer OS. Further investigations of predictive biomarkers are
necessary to better characterize this subgroup of patients and develop further de-escalating strategies.
Trial registration: NCT00004935; first posted 27.01.2003, retrospectively registered.
Keywords: HER-positive breast cancer, Trastuzumab monotherapy, Long-term responders
Background
About 15–20% of breast cancers overexpress HER2: in
advanced breast cancer (ABC), HER2-targeted therapies
significantly improve disease outcomes [1, 2]. Before the
introduction of dual HER2-blockade (trastuzumab plus
pertuzumab) in combination with chemotherapy [3] and
trastuzumab emtansine (T-DM1) [4] as recommended
first and second line therapy, respectively, trastuzumab
in combination with chemotherapy was the standard of
care. The impact of trastuzumab monotherapy followed
by the addition of chemotherapy at disease progression
(PD) versus upfront combination therapy was explored
in the Swiss Group for Clinical Cancer Research (SAKK)
22/99 trial, a randomized phase III trial of sequential
versus combination therapy in patients with HER2-posi-
tive ABC. The primary endpoint was time to progression
after combination therapy (combination TTP). The re-
cently published results [5], showed that both combin-
ation TTP and OS did not significantly differ between
arms, suggesting that chemotherapy and its toxicity can
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be deferred, especially in patients with indolent, non-vis-
ceral disease. In particular, although the median TTP in
the trastuzumab monotherapy arm was only 3.7 months,
6% of patients treated with single agent trastuzumab
were still on treatment without PD after 2 years. This
suggests that trastuzumab monotherapy may achieve
long-term disease control in a subset of patients, in
whom we can avoid upfront combination immuno-
chemotherapy.
The aim of this unplanned analysis of the SAKK 22/99
trial was to characterize this specific subset of patients
and to identify potential predictive factors of long-term
response.
Methods
SAKK 22/99 accrued patients from November 1999 to
January 2013 [5]. This was a multicentre, prospective,
non-blinded, randomized phase III trial. Patients with
HER2-positive ABC were randomly assigned (1:1) to tras-
tuzumab alone followed, at PD, by the combination with
chemotherapy (Arm A) versus the upfront combination of
trastuzumab and chemotherapy (Arm B). Chemotherapy
could be stopped after six cycles in responding patients,
trastuzumab was continued until progression.
Patients were stratified for HER2-ratio, adjuvant anthra-
cyclines, estrogen/progesteron receptor (ER/PgR) status,
line of treatment and institution. The primary trial end-
point was TTP on combined trastuzumab-chemotherapy
(combination TTP) in both arms. The median follow-up
was 77months. SAKK 22/99 study design and methods
have been previously described [5].
In this unplanned post-hoc analysis we focused on
patients randomized to Arm A (trastuzumab mono-
therapy). We divided Arm A patients in two groups:
long-term responders: patients with durable clinical
benefit from trastuzumab monotherapy and short-
term responders without clinical benefit to trastuzu-
mab monotherapy (Fig. 1: Flow Chart). Durable
clinical benefit was defined as complete response
(CR), partial response (PR) or stable disease (SD) as
best overall response that persisted for a minimum of
24 weeks. The cut-off of 24 weeks was chosen a priori
based on the definition of durable clinical benefit
commonly used in clinical trials [6, 7]. Twenty four
weeks corresponds also well to the median response
duration achieved with modern HER2-targeted therap-
ies [8].
The primary outcome of interest for this study was OS,
defined as time from randomization to death of any cause
or censored at the last date the patient was known to be
alive. To account for the immortal-time bias introduced
by the definition of the groups with long or short clinical
benefit we applied the landmark analysis method [7] for
both the Kaplan-Meier method and uni- and multivariable
Cox proportional hazards regression models. Standard de-
scriptive measures such as median and interquartile range
for continuous variables and absolute and relative fre-
quencies for categorical variables were applied as appro-
priate and indicated in the text.
We analysed the following characteristics known to be
associated with durable clinical benefit: visceral disease,
ER/PgR expression, and the HER2:CEP17 ratio. Ki67
and tumour grade were not considered since not col-
lected in the trial database.
P-values are two-sided and considered significant if <
0.05. No adjustment was made for multiple testing. Analyses
were carried out using SAS v9.2 or the R software package
(https://www.r-project.org) version 3.2 or later.
Fig. 1 Flow-Chart
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Results
Of the 175 patients enrolled in the trial, 87 were rando-
mised to receive trastuzumab monotherapy until PD and
86 ultimately received treatment according to protocol. Of
these, 24 patients (28%) were long-term responders with
durable clinical benefit and 62 (72%) were short-term re-
sponders according to the definition above (see Fig. 1).
Baseline characteristics such as age, prior endocrine
therapy and ER/PgR expression were not different be-
tween the two groups when retrospectively analysed;
this also holds true for laboratory values such as
haemoglobin (Hb), white blood cell count (WBC) and
alkaline phosphatase (ALP), which have been shown
to be prognostic for OS in ABC [9]. The presence of
visceral disease was the only variable correlated with
durable clinical benefit, with only 46% of patients
with visceral disease at time of randomisation being
long-term responders compared to 76% in the short-
term responders group (Fisher’s exact test p = 0.01)
(Table 1: Baseline Characteristics of long-term versus
short-term responders).
When analysing the combination of possible negative
predictive factors (NPF) such as absence of ER and PgR
expression and presence of visceral disease and associat-
ing them with the duration of benefit from trastuzumab
monotherapy, the proportion of long-term responders
decreased with the presence of each additional NPF: 0
NPF 42%; 1 NPF 40%; 2 NPFs 35%; 3 NPFs 17%.
In a landmark analysis excluding patients who died
within the first 6 months, the group of long-term re-
sponders to trastuzumab monotherapy showed a 5-year
OS rate of 54% (95% CI 31–72) compared to only 18%
(95% CI 10–30) among the short-term responders (log-
rank p = 0.02) (Fig. 2: OS of long-term versus short-term
responders).
In a multivariate analysis adjusted for visceral disease,
durable clinical benefit from trastuzumab monotherapy
remained significantly associated with OS (HR of 0.54,
95% CI 0.30–0.97, p-value: 0.04), suggesting long-term
response to trastuzumab monotherapy correlates with
long-term survival.
Regarding the degree of HER2 overexpression, we
found a median FISH ratio of 4.8 (IQR 4.1–5.3) in long-
term responders and of 4.7 (IQR 2.5–5.3) in short-term
responders, respectively, showing a numerical, but not
statistically significant difference in the first quartile.
However, in the lowest quartile of all FISH ratios (≤3.4)
there were only 3 (17%) long-term responders compared
to 15 (83%) short responders.
Treatment patterns after PD in the group of long-term
responders were very diverse. After trial treatment, pa-
tients received a median of 4 post-progression treatment
lines, with some patients receiving up to 12 additional
treatment lines. The majority of patients were treated
with chemotherapy, either alone or in combination with
HER2-directed treatments. Twenty-nine percent of pa-
tients also received one or several lines of endocrine
treatment (monotherapy or in combination) in the
course of their disease (Fig. 3: Patterns of care of long-
term responders including follow-up treatment).
Discussion
In this explorative analysis of the SAKK 22/99 trial we
identified a subset of patients who derived long-term
benefit from trastuzumab monotherapy and we show
that long-term response is predictive for OS in a land-
mark analysis.
Current clinical research in HER2-positive ABC focuses
on both upfront combination treatment approaches and
de-escalating strategies. The triplet combination of trastu-
zumab, pertuzumab and chemotherapy as 1st-line treat-
ment is considered the standard of care, showing a
significant OS benefit of 15.7months versus the double
combination trastuzumab and chemotherapy in the
CLEOPATRA trial [3]. But, as demonstrated in the SAKK
22/99 trial, a subset of patients may actually have long-
term disease control with trastuzumab alone, sparing or at
least postponing the toxicity of chemotherapy without
Table 1 Baseline Characteristics of long-term versus short-term responders
HER2-long Responders (N = 24) HER2-short Responders (N = 62)
Age (med, IQR) 57 years (48–67) 52 years (32–60)
Visceral disease (yes) 46% 76%
ER-Status (pos) 59% 60%
PgR-Status (pos) 48% 41%
FISH (med. Ratio, IQR) 4.8 (4.1–5.3) 4.7 (2.5–5.3)
ALP U/l (med, IQR) 74 (62–118) 103 (65–193)
Hb g/l (med, IQR) 130 (122–137) 134 (125–140)
WBC G/l (med, IQR) 5.8 (5.1–6.7) 6.8 (6.0–8.5)
Adjuvant endocrine treatment (yes) 33% 48%
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Fig. 2 OS of long-term versus short-term responders
Fig. 3 Patterns of care of long-term responders including follow-up treatment
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compromising outcomes. Due to the lack of valid predict-
ive biomarkers allowing early and effective identification
of this specific subgroup of patients, in routine clinical
practice patients are usually treated upfront with combin-
ation immuno-chemotherapy.
In this report, focusing specifically on patients treated
with upfront trastuzumab monotherapy within a random-
ized clinical trial, we demonstrate that about a quarter of
patients with advanced HER2-positive disease had at least
6months disease control with single agent trastuzumab.
This so-called durable clinical benefit to initial trastuzumab
monotherapy was associated with an OS benefit compared
to patients with short-term response. Potential factors asso-
ciated with short-term response were the presence of vis-
ceral disease at randomization and numerically, but not
statistically significant, potentially due to small numbers
and availability in a subset of patients only, low HER2 FISH
ratio. Visceral disease in combination with ER/PgR expres-
sion and possibly HER2 FISH ratio shows some association
with the duration of treatment response. This is in line with
previous reports of factors associated with long-term sur-
vivorship in patients with HER2-positive metastatic breast
cancer [10, 11].
However, none of these parameters, alone or in combin-
ation, allows a highly reliable discrimination between the
two patient groups and further investigation of predictive
biomarkers is needed to improve the predictive value of
such clinical factors.
Two other trials evaluated upfront HER2-targeted
treatment alone followed by combination treatment
versus upfront combination: the JO17360 trial assessed
trastuzumab followed by trastuzumab and docetaxel at
progression versus the upfront combination [12],
whereas in the HERTAX trial trastuzumab followed by
docetaxel alone at disease progression was compared to
the upfront combination [13]. In both trials the upfront
combination therapy was associated with superior OS
compared to the sequencing approach achieving statis-
tical significance only in the JO17360 trial. The conclu-
sion from both trials was that their data do not support
a sequential antibody-strategy. Interestingly, in the
HERTAX trial a small subset of patients derived long-
term benefit from trastuzumab alone: 16 and 4 patients
(out of the 45 randomized in the sequential arm) were
not progressing on trastuzumab monotherapy at 6 and
12 months, respectively. Unfortunately, the characteris-
tics of these patients were not analysed in more detail.
It would be interesting to pool all the three trials data-
sets to investigate and possibly validate predictive clin-
ical factors for this subgroup of patients. Another more
recent SAKK trial (22/10) investigated a similar treat-
ment strategy by comparing the more active dual
HER2-blockade alone versus upfront combination with
chemotherapy both followed by T-DM1 at PD and first
results were now presented at ESMO showing no im-
pact on survival when deferring chemotherapy [14] and
therefore support our results..
Our analysis clearly demonstrates that long-term response
to trastuzumab monotherapy is predictive for OS with a 5-
year OS of 54% in long-term responders versus only 18% in
short-term responders. It would be of great clinical import-
ance to prospectively characterize this good prognosis sub-
group potentially de-escalate treatment and spare some
patients the chemotherapy-related toxicities. This approach
would also enhance cost-effectiveness as recently addressed
by Nixon et al. [8].
Treatment patterns after PD in the group of long-term
responders were very diverse: the majority of patients
were treated with chemotherapy-based regimes. Thus,
chemotherapy-related toxicity was significantly postponed
due to the initial HER2-targeted monotherapy approach.
However, the vast majority of patients received chemo-
therapy as well as endocrine treatments patients at some
point in their disease course and therefore de-escalation of
treatment in most cases has to be understood as a defer-
ring approach. This approach has been already adopted in
clinical practice mainly based on general principles usually
used in the management of metastatic breast cancer and
on clinical experience treating physicians [15].
This analysis has a number of limitations: First, this is
an unplanned analysis with a relatively small sample size.
Durable clinical benefit, though now often used in bio-
marker trials in the immunotherapy era, is not common
hard endpoint in randomized trial. However, the 6
months cut-off is used for categorising clinical benefit
when investigating efficacy endocrine treatment, another
targeted therapy. Additional prognostic factors currently
considered relevant, such as Ki67 and grading, were not
systematically collected and thus were not included in
the analysis. In addition intrinsic subtypes as defined by
the PAM50 test can also predict response to anti-HER2-
treatment [16], but were not available at the time point
the trial was designed and conducted. This was an ex-
ploratory retrospective investigation of a prospective
randomized trial and the results can be considered hy-
pothesis generating for further de-escalating research
strategies. The observations, including low HER2- copy
as a negative predictive marker, arguing for antibody
therapy without chemotherapy in selected patients, de-
serves further investigation in an independent data set.
Our preliminary findings nevertheless reinforce the pre-
viously reported information [5] that de-escalation strat-
egies may be discussed in individual patients with
HER2-positive ABC.
Conclusion
Durable clinical benefit can be achieved with trastuzu-
mab monotherapy in a subgroup of HER2-positive
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patients with advanced disease and it is predictive for
longer OS.
Further investigation of predictive biomarkers is needed
to better characterize this subgroup of patients and inform
further de-escalating strategies.
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